Work

Phase I study of low-dose suramin as a chemosensitizer in patients with advanced non-small cell lung cancer.

Year: 2003

Type: article

Study design: Clinical Trial

Source: PubMed

Authors: Miguel A Villalona-Calero, M Guillaume Wientjes, Gregory A Otterson, Steven Kanter, Donn Young, Anthony J Murgo, Beth Fischer, Carrie DeHoff, Danny Chen, Teng-Kuang Yeh, SaeHeum Song, Michael Grever, Jessie L-S Au

Institutions: The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, National Cancer Institute, The Ohio State University

Language: English

Topic: Lung Cancer Treatments and Mutations

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: National Cancer Institute, National Center for Research Resources

Awards: PHARMACODYNAMICS OF AGENTS FOR BLADDER CANCER THERAPY, Phase I Trials of Anti-Cancer Agents, Suramin to Enchance Paclitaxel and Carboplatin in NSCLC, General Clinical Research Center

OpenAlex ID: W2145758314

FWCI: 2.322

Cites: 67

Cited by: 39

Related to: 10